Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(7):425; doi:10.1093/jnci/djj157
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Isotretinoin and Prevention of Second Primary Tumors

High-dose isotretinoin (13-cis-retinoic acid) has produced encouraging results in patients with head and neck squamous cell cancer (HNSCC). However, the toxic effects of high-dose isotretinoin are substantial. Khuri et al. (p. 441) conducted a phase III randomized trial of low-dose isotretinoin (30 mg/day) versus placebo in 1190 early-stage HNSCC patients to assess its effect on second primary tumor incidence and survival. After 3 years of study drugs and up to 4 years of additional follow-up, isotretinoin did not reduce the rate of second primary tumors or increase survival. Among isotretinoin-treated patients, current smokers had a . . . [Full Text of this Article]

Vitamin D Status and Cancer Risk in Men

Soy Intake and Breast Cancer Risk

Gene Expression Profiling and Melanoma Outcome

Serum Retinol and Hepatocellular Carcinoma Risk

Grb7 Peptide Inhibitor and Pancreatic Cancer Metastasis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?